Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?

Tesson, Stephanie; Richards, Imogen; Porter, David; Phillips, Kelly Anne; Rankin, Nicole; Costa, Daniel; Musiello, Toni; Marven, Michelle; Butow, Phyllis

doi:10.1016/j.breast.2016.11.025

Cited by 11 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For 24 studies for which IPD was not available, aggregate data could be obtained from the articles. Fifteen studies reported data on the mean FCR score 33,[73][74][75][76][77][78][79][80][81][82][83][84][85][86] ; and 12 studies reported data on the percentage scoring ≥13. 73,76,78,82,83,[86][87][88][89][90][91][92] The other studies reported neither outcome.…”

Section: Resultsmentioning

confidence: 99%

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Objective Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI‐SF). We also report on associations between FCR and clinical and demographic characteristics. Methods This is a systematic review and individual participant data (IPD) meta‐analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI‐SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI‐SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185).

show abstract

Section: Resultsmentioning

confidence: 99%

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The decision‐making process for the election of CPM is complex and entails several driving forces, including the possible anxiety of receiving a positive genetic testing result. Studies suggest that CPM election may also be influenced by biopsies, screening costs and fatigue, cosmetic considerations, psychological factors, and perceived emotional advantages of CPM, among others . Also, these patients had to make their decision about CPM on the basis of the treatment planned for their unilateral breast cancer, so their desire to avoid repeated treatment (CBC) could have influenced the decision.…”

Section: Discussionmentioning

confidence: 99%

“…Our study indicates that patients are still opting for CPM as a measure of prevention even though substantive data on the potential need for this surgery is unavailable. It is also important to note that there are potential harms associated with CPM, such as postsurgical complications and concerns with body image, femininity, and sexuality . It is not clear that increased CPM in non‐ BRCA carriers will improve disease‐specific or overall survival.…”

Section: Discussionmentioning

confidence: 99%

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer

et al. 2018

View full text Add to dashboard Cite

Although multigene panel testing is increasingly common in patients with cancer, the relationship between its use among breast cancer patients with non‐BRCA mutations or variants of uncertain significance (VUS) and disease management decisions has not been well described. This study evaluated the rate and predictive factors of CPM patients who underwent multigene panel testing. Three hundred and fourteen patients with breast cancer who underwent multigene panel testing between 2014 and 2017 were included in the analysis. Of the 314 patients, 70 elected CPM. Election of CPM by gene status was as follows: BRCA carriers (42.3%), non‐BRCA carriers (30.1%), and VUS (10.6%). CPM election rates did not differ between non‐BRCA carriers and BRCA carriers (P = 0.6205). Among non‐BRCA carriers, negative hormone receptor status was associated with CPM (P = 0.0115). For those with a VUS, hormone receptor status was not associated with CPM (P = 0.1879). Although the rate of CPM between BRCA carriers and non‐BRCA carriers was not significantly different, the predictors of CPM were different in each group. Our analyses shed the light on the increasing use of CPM among patients who are non‐BRCA carriers as well those with a VUS. Our study elucidates the differing predictive factors of CPM election among BRCA carriers, non‐BRCA carries, and those with a VUS. Our findings reveal the need for providers to be cognizant that non‐BRCA genes and VUS drive women to elect CPM despite the lack of data for contralateral breast cancer risk associated with these genes.

show abstract

“…Consistent with functional accounts of emotions (Frijda, 1986), results have shown that this fear serves an important purpose by motivating people to engage in behaviors that can protect health (Mayne, 1999). For example, people who felt afraid of breast cancer were more likely to consider procedures to reduce their risk of developing breast cancer (Tesson et al, 2017), those who felt afraid of sexually transmitted infections were more willing to take a screening test (Shepherd & Smith, 2017), and parents who felt afraid that their child would contract measles were more likely to have their child vaccinated (Feigelman et al, 1993). This evidence suggests that although fear is unpleasant, it can effectively motivate people to engage in behaviors that protect their physical health—and even their community’s health, in the case of communal health risks.…”

Section: The Role Of Fear In Responding To Health Threatsmentioning

confidence: 99%

Coping With Health Threats: The Costs and Benefits of Managing Emotions

Smith

Willroth²,

Gatchpazian

et al. 2021

Psychol Sci

View full text Add to dashboard Cite

How people respond to health threats can influence their own health and, when people are facing communal risks, even their community’s health. We propose that people commonly respond to health threats by managing their emotions with cognitive strategies such as reappraisal, which can reduce fear and protect mental health. However, because fear can also motivate health behaviors, reducing fear may also jeopardize health behaviors. In two diverse U.S. samples ( N = 1,241) tracked across 3 months, sequential and cross-lagged panel mediation models indicated that reappraisal predicted lower fear about an ongoing health threat (COVID-19) and, in turn, better mental health but fewer recommended physical health behaviors. This trade-off was not inevitable, however: The use of reappraisal to increase socially oriented positive emotions predicted better mental health without jeopardizing physical health behaviors. Examining the costs and benefits of how people cope with health threats is essential for promoting better health outcomes for individuals and communities.

show abstract

Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?

Cited by 11 publications

References 36 publications

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer

Coping With Health Threats: The Costs and Benefits of Managing Emotions

Contact Info

Product

Resources

About